$48.82
5.20% today
Nasdaq, Apr 03, 06:48 pm CET
ISIN
US87650L1035
Symbol
TARS
Sector
Industry

Tarsus Pharmaceuticals Inc Stock price

$51.49
+8.77 20.53% 1M
+18.74 57.22% 6M
-3.88 7.01% YTD
+15.91 44.72% 1Y
+34.03 194.90% 3Y
+35.49 221.81% 5Y
+35.49 221.81% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+2.57 5.25%
ISIN
US87650L1035
Symbol
TARS
Sector
Industry

Key metrics

Market capitalization $2.14b
Enterprise Value $1.92b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.51
P/S ratio (TTM) P/S ratio 11.71
P/B ratio (TTM) P/B ratio 8.79
Revenue growth (TTM) Revenue growth 948.62%
Revenue (TTM) Revenue $182.95m
EBIT (operating result TTM) EBIT $-120.57m
Free Cash Flow (TTM) Free Cash Flow $-84.59m
Cash position $291.38m
EPS (TTM) EPS $-3.10
P/E forward negative
P/S forward 6.05
EV/Sales forward 5.43
Short interest 18.58%
Show more

Is Tarsus Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Tarsus Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:

Buy
88%
Hold
13%

Financial data from Tarsus Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
183 183
948% 948%
100%
- Direct Costs 13 13
407% 407%
7%
170 170
1,041% 1,041%
93%
- Selling and Administrative Expenses 236 236
122% 122%
129%
- Research and Development Expense 53 53
6% 6%
29%
-119 -119
16% 16%
-65%
- Depreciation and Amortization 1.24 1.24
4% 4%
1%
EBIT (Operating Income) EBIT -121 -121
16% 16%
-66%
Net Profit -116 -116
15% 15%
-63%

In millions USD.

Don't miss a Thing! We will send you all news about Tarsus Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tarsus Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
22 days ago
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 421,348 shares of ...
Neutral
GlobeNewsWire
22 days ago
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the prop...
Positive
Seeking Alpha
23 days ago
Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project Tarsus' revenue to reach $352M in 2025, driven by expanding sales, Medicare/Medicaid reimbursement, and increasing consumer awareness. Tarsus' pipeline includes promising candidates TP-04 for Ocular...
More Tarsus Pharmaceuticals Inc News

Company Profile

Tarsus Pharmaceuticals, Inc. develops and manufactures drug treatments for Blepharitis. The company focuses on treatment of Blepharitis, which is a common ocular condition, characterized by inflammation of the eyelid, which can impact the anterior or posterior lid or both. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Head office United States
CEO Bobak Azamian
Employees 323
Founded 2017
Website tarsusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today